(vianews) - after two consecutive sessions of losses, shares of ab science (ab.pa) on the cac 40 saw an unexpected 13.87% surge to eur3.33 at 16:18 est thursday at 16:18, reversing their downward trend for an upward trading session thus far. last closing price for ab science on thursday was eur2.92, which was 69.26% below its 52-week high of eur9.50.
about ab science
ab science s.a. is a pharmaceutical company dedicated to researching, developing and marketing protein kinase inhibitors for human and veterinary medicines. their lead compound masitinib, a tyrosine kinase inhibitor currently undergoing phase iii trials for prostate and pancreatic cancer as well as severe asthma, alzheimer's dementia and mastocytosis (along with covid-19 treatment), as well as phase ii trials in haematology indications; it's also sold under europe under its brand name masivet brand name). established in 2001 based out of paris france
yearly analysis
at its current price of eur3.33, ab science's stock is trading at a substantial discount to its 52-week high of eur9.50; yet still remains above its 52-week low of eur2.73. this suggests that its share prices have fluctuated throughout this past year, with current levels being closer to the lower end of that spectrum. as investors should keep in mind, past performance does not guarantee future returns, and investors should conduct their own analysis, taking into account factors like financial health of a company, industry trends and overall market conditions when making investment decisions.
technical analysis
ab science's stock price is trading significantly below both its 50-day and 200-day moving averages, suggesting a potential downward trend over both short and long terms. this could be cause for concern among investors looking for stocks with upward trends. noteworthy is today's trading volume of 401,034 shares which is 220.69% higher than its average volume of 125,052. this could signal increased interest and indicate that there may be hope for an imminent comeback for this stock. over the last week, intraday volatility for this stock has been positive at 0.74% indicating a slight upward trend compared to negative volatility of 1.69% over the last month and 2.94% over the last quarter. overall, investors should monitor ab science's moving averages and trading volume as indicators of potential price movements. furthermore, monitoring its volatility can offer insight into whether its trend might rebound or remain downward.
quarter analysis
based on the information available, revenue growth at this company has seen a substantial decrease year-on-year of 58.3%, leading to current revenues of 958k for twelve trailing months. this indicates that revenue growth may have significantly slowed, prompting concern from investors. but investors must remember that revenue growth alone doesn't provide a complete picture of a company's financial health; before making investment decisions they should also consider factors like profitability, cash flow and the general economic climate. investors should conduct an in-depth examination of a company's financial statements, management team, and industry trends to gauge its potential for future growth and profitability.
equity analysis
based on available information, ab science has reported a trailing twelve months eps of eur-0.31. eps measures earnings per share to evaluate a company's profitability; when negative, it means the business experienced losses during its last 12 month period and may indicate financial troubles to potential investors. however, investors must remember that earnings per share (eps) should only be seen as one piece of information when assessing stocks. investors must take other factors such as revenue growth, industry trends, market conditions and cash flow statements into consideration as well. finally, reviewing each company's financial statements such as balance sheet, income statement and cash flow statement to gain an in-depth knowledge of their health is necessary in making sound investment decisions. overall, investors should exercise extreme caution when investing in ab science given its negative eps performance and conduct additional research to ascertain if its financials meet with their investment goals.
more news about ab science (ab.pa).